{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:48:30Z","timestamp":1786373310461,"version":"build-2736575974"},"reference-count":104,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>People with kidney failure can experience a range of symptoms that lead to suffering and poor quality of life. Available therapies are limited, and evidence for new treatment options is sparse, often resulting in incomplete relief of symptoms. There is growing interest in the potential for cannabinoids, including cannabidiol and tetrahydrocannabinol, to treat symptoms across a wide range of chronic diseases. As legal prohibitions are withdrawn or minimized in many jurisdictions, patients are increasingly able to access these agents. Cannabinoid receptors, CB1 and CB2, are widely expressed in the body, including within the nervous and immune systems, and exogenous cannabinoids can have anxiolytic, antiemetic, analgesic, and anti-inflammatory effects. Considering their known physiologic actions and successful studies in other patient populations, cannabinoids may be viewed as potential therapies for a variety of common symptoms affecting those with kidney failure, including pruritus, nausea, insomnia, chronic neuropathic pain, anorexia, and restless legs syndrome. In this review, we summarize the pharmacology and pharmacokinetics of cannabinoids, along with what is known about the use of cannabinoids for symptom relief in those with kidney disease, and the evidence available concerning their role in management of common symptoms. Presently, although these agents show varying efficacy with a reasonable safety profile in other patient populations, evidence-based prescribing of cannabinoids for people with symptomatic kidney failure is not possible. Given the symptom burden experienced by individuals with kidney failure, there is an urgent need to understand the tolerability and safety of these agents in this population, which must ultimately be followed by robust, randomized controlled trials to determine if they are effective for symptom relief.<\/jats:p>","DOI":"10.2215\/cjn.11560821","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T14:35:15Z","timestamp":1641393315000},"page":"911-921","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Cannabinoids for Symptom Management in Patients with Kidney Failure"],"prefix":"10.2215","volume":"17","author":[{"given":"Hayley","family":"Worth","sequence":"first","affiliation":[{"name":"Department of Palliative Medicine, St George Hospital, Kogarah, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-8860","authenticated-orcid":false,"given":"Daniel V.","family":"O\u2019Hara","sequence":"additional","affiliation":[{"name":"Kidney Health Division, NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeru","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Kidney Health Division, NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2323-6521","authenticated-orcid":false,"given":"David","family":"Collister","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Department of Medicine, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Brennan","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, St George Hospital, Kogarah, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Smyth","sequence":"additional","affiliation":[{"name":"Kidney Health Division, NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia"},{"name":"Department of Renal Medicine, St George Hospital, Kogarah, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: A systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0269216306070236","article-title":"Comparative pilot study of symptoms and quality of life in cancer patients and patients with end-stage renal disease","volume":"20","author":"Saini","year":"2006","journal-title":"Palliat Med"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.ackd.2006.10.001","article-title":"The prevalence of symptoms in end-stage renal disease: A systematic review","volume":"14","author":"Murtagh","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.00430109","article-title":"Symptom burden, depression, and quality of life in chronic and end-stage kidney disease","volume":"4","author":"Abdel-Kader","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.ajkd.2009.07.017","article-title":"Association between achievement of hemodialysis quality-of-care indicators and quality-of-life scores","volume":"54","author":"Lacson","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/j.ajkd.2016.11.029","article-title":"Developing a set of core outcomes for trials in hemodialysis: An international Delphi survey","volume":"70","author":"Evangelidis","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B11-20241015","first-page":"CD011393","article-title":"Interventions for itch in people with advanced chronic kidney disease","volume":"12","author":"Hercz","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/ndt\/gfz097","article-title":"Comparative efficacy and acceptability of treatments for restless legs syndrome in end-stage renal disease: A systematic review and network meta-analysis","volume":"35","author":"Huang","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20241015","first-page":"CD012625","article-title":"Interventions for improving sleep quality in people with chronic kidney disease","volume":"5","author":"Natale","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B14-20241015","first-page":"CD004542","article-title":"Psychosocial interventions for preventing and treating depression in dialysis patients","volume":"12","author":"Natale","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"B15-20241015","first-page":"CD004541","article-title":"Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis","author":"Palmer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1681\/ASN.2018010096","article-title":"Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients","volume":"29","author":"Ishida","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2215\/CJN.09910917","article-title":"Opioid analgesics and adverse outcomes among hemodialysis patients","volume":"13","author":"Ishida","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"2054358120954944","DOI":"10.1177\/2054358120954944","article-title":"Cannabis use for restless legs syndrome and uremic pruritus in in patients treated with maintenance dialysis: A survey","volume":"7","author":"Samaha","year":"2020","journal-title":"Can J Kidney Health Dis"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jpainsymman.2020.08.003","article-title":"Nephrologist views regarding cannabinoid use in advanced chronic kidney disease and dialysis: A survey","volume":"61","author":"Collister","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"2054358119828391","DOI":"10.1177\/2054358119828391","article-title":"A review of cannabis in chronic kidney disease symptom management","volume":"6","author":"Ho","year":"2019","journal-title":"Can J Kidney Health Dis"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jpainsymman.2010.06.016","article-title":"Is there a legitimate role for the therapeutic use of cannabinoids for symptom management in chronic kidney disease?","volume":"41","author":"Davison","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s13063-020-04541-6","article-title":"Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: A double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"21","author":"Hardy","year":"2020","journal-title":"Trials"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-014-0195-5","article-title":"Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics","volume":"54","author":"Heuberger","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/phar.2512","article-title":"Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies","volume":"41","author":"Silmore","year":"2021","journal-title":"Pharmacotherapy"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-030-61663-2_3","article-title":"Clinical pharmacokinetics of cannabinoids and potential drug-drug interactions","volume":"1297","author":"V\u00e1zquez","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000507998","article-title":"Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions","volume":"3","author":"Kocis","year":"2020","journal-title":"Med Cannabis Cannabinoids"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front Pharmacol"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40262-019-00841-6","article-title":"A phase i, open-label, parallel-group, single-dose trial of the pharmacokinetics, safety, and tolerability of cannabidiol in subjects with mild to severe renal impairment","volume":"59","author":"Tayo","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/ndt\/gfr616","article-title":"Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins","volume":"27","author":"Klammt","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","article-title":"Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance","volume":"15","author":"Allen","year":"2014","journal-title":"Sleep Med"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-030-61663-2_13","article-title":"Cannabis for restless legs syndrome","volume":"1297","author":"Ghorayeb","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2215\/CJN.10510917","article-title":"Recommendations for the care of patients receiving conservative kidney management: Focus on management of CKD and symptoms","volume":"14","author":"Davison","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.27260","article-title":"Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)","volume":"33","author":"Winkelmann","year":"2018","journal-title":"Mov Disord"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1212\/WNL.0000000000002803","article-title":"Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?","volume":"87","author":"Heim","year":"2016","journal-title":"Neurology"},{"key":"B36-20241015","first-page":"CD006939","article-title":"Benzodiazepines for restless legs syndrome","volume":"3","author":"Carlos","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B37-20241015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol Res"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1212\/WNL.0000000000001013","article-title":"Synaptic effects of cannabinoids: Complexity, behavioral effects, and potential clinical implications","volume":"83","author":"Benarroch","year":"2014","journal-title":"Neurology"},{"key":"B39-20241015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nature20153","article-title":"The effects of \u03949-tetrahydrocannabinol on the dopamine system","volume":"539","author":"Bloomfield","year":"2016","journal-title":"Nature"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.biopsych.2013.05.027","article-title":"Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms","volume":"75","author":"Bloomfield","year":"2014","journal-title":"Biol Psychiatry"},{"key":"B41-20241015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11325-019-01978-1","article-title":"More evidence of cannabis efficacy in restless legs syndrome","volume":"24","author":"Ghorayeb","year":"2020","journal-title":"Sleep Breath"},{"key":"B42-20241015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.sleep.2017.04.019","article-title":"Cannabis for restless legs syndrome: A report of six patients","volume":"36","author":"Megelin","year":"2017","journal-title":"Sleep Med"},{"key":"B43-20241015","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000518391","article-title":"Chronic kidney disease-associated pruritus: A review","volume":"46","author":"Makar","year":"2021","journal-title":"Kidney Blood Press Res"},{"key":"B44-20241015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40261-020-00894-7","article-title":"Mechanisms of cannabinoids and potential applicability to skin diseases","volume":"40","author":"Cintosun","year":"2020","journal-title":"Clin Drug Investig"},{"key":"B45-20241015","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2018.08.022","article-title":"The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders","volume":"157","author":"R\u00edo","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B46-20241015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.lfs.2010.06.003","article-title":"Effects of cannabinoids on capsaicin receptor activity following exposure of primary sensory neurons to inflammatory mediators","volume":"87","author":"Soneji","year":"2010","journal-title":"Life Sci"},{"key":"B47-20241015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejphar.2017.07.007","article-title":"\u03b22-Microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1","volume":"810","author":"Andoh","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"B48-20241015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1159\/000188949","article-title":"Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream","volume":"72","author":"Tarng","year":"1996","journal-title":"Nephron"},{"key":"B49-20241015","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B50-20241015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ndt\/gfi204","article-title":"The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients","volume":"21","author":"Kimmel","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B51-20241015","first-page":"97","article-title":"Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: A preliminary study","volume":"13","author":"Szepietowski","year":"2005","journal-title":"Acta Dermatovenerol Croat"},{"key":"B52-20241015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/nep.13236","article-title":"Effect of extended hours dialysis on sleep quality in a randomized trial","volume":"24","author":"Liao","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"B53-20241015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","article-title":"Cannabis, cannabinoids, and sleep: A review of the literature","volume":"19","author":"Babson","year":"2017","journal-title":"Curr Psychiatry Rep"},{"key":"B54-20241015","doi-asserted-by":"crossref","first-page":"e034421","DOI":"10.1136\/bmjopen-2019-034421","article-title":"Cannabidiol (CBD) and \u03949-tetrahydrocannabinol (THC) for chronic insomnia disorder (\u2018CANSLEEP\u2019 trial): Protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial","volume":"10","author":"Suraev","year":"2020","journal-title":"BMJ Open"},{"key":"B55-20241015","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.smrv.2020.101339","article-title":"Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies","volume":"53","author":"Suraev","year":"2020","journal-title":"Sleep Med Rev"},{"issue":"Suppl 1","key":"B56-20241015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B57-20241015","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.jrn.2019.11.004","article-title":"The pathophysiology and management of taste changes in chronic kidney disease: A review","volume":"30","author":"Brennan","year":"2020","journal-title":"J Ren Nutr"},{"key":"B58-20241015","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1007\/s00213-016-4397-4","article-title":"Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats","volume":"233","author":"Brierley","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"B59-20241015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0031-9384(98)00170-X","article-title":"Hyperphagia in pre-fed rats following oral delta9-THC","volume":"65","author":"Williams","year":"1998","journal-title":"Physiol Behav"},{"key":"B60-20241015","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/bph.13226","article-title":"Role of the endocannabinoid system in diabetes and diabetic complications","volume":"173","author":"Gruden","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B61-20241015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0885-3924(94)00117-4","article-title":"Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS","volume":"10","author":"Beal","year":"1995","journal-title":"J Pain Symptom Manage"},{"key":"B62-20241015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/QAI.0b013e31811ed205","article-title":"Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep","volume":"45","author":"Haney","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B63-20241015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00213-005-2242-2","article-title":"Dronabinol and marijuana in HIV(+) marijuana smokers: Acute effects on caloric intake and mood","volume":"181","author":"Haney","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"B64-20241015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/eat.22173","article-title":"Dronabinol in severe, enduring anorexia nervosa: A randomized controlled trial","volume":"47","author":"Andries","year":"2014","journal-title":"Int J Eat Disord"},{"key":"B65-20241015","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","article-title":"Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group","volume":"24","author":"Strasser","year":"2006","journal-title":"J Clin Oncol"},{"key":"B66-20241015","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: A randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"key":"B67-20241015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/sdi.12196","article-title":"Pain in chronic kidney disease: A scoping review","volume":"27","author":"Davison","year":"2014","journal-title":"Semin Dial"},{"key":"B68-20241015","doi-asserted-by":"crossref","first-page":"E8870","DOI":"10.3390\/ijms21228870","article-title":"Cannabidiol for pain treatment: Focus on pharmacology and mechanism of action","volume":"21","author":"Mlost","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B69-20241015","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: A systematic review and meta-analysis of controlled and observational studies","volume":"159","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"B70-20241015","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: A systematic review and meta-analysis","volume":"320","author":"Busse","year":"2018","journal-title":"JAMA"},{"key":"B71-20241015","doi-asserted-by":"crossref","first-page":"e023736","DOI":"10.1136\/bmjopen-2018-023736","article-title":"Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol","volume":"9","author":"Smyth","year":"2019","journal-title":"BMJ Open"},{"key":"B72-20241015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcn.2015.02.001","article-title":"The importance of TRPV1-sensitisation factors for the development of neuropathic pain","volume":"65","author":"Malek","year":"2015","journal-title":"Mol Cell Neurosci"},{"key":"B73-20241015","doi-asserted-by":"crossref","first-page":"1744806919881038","DOI":"10.1177\/1744806919881038","article-title":"The role of urea in neuronal degeneration and sensitization: An in vitro model of uremic neuropathy","volume":"15","author":"Anand","year":"2019","journal-title":"Mol Pain"},{"key":"B74-20241015","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2147\/JPR.S258433","article-title":"CBD effects on TRPV1 signaling pathways in cultured DRG neurons","volume":"13","author":"Anand","year":"2020","journal-title":"J Pain Res"},{"key":"B75-20241015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/can.2019.0028","article-title":"Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent","volume":"5","author":"Gray","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"B76-20241015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid ligands targeting TRP channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"B77-20241015","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jpain.2015.07.009","article-title":"Inhaled cannabis for chronic neuropathic pain: A meta-analysis of individual patient data","volume":"16","author":"Andreae","year":"2015","journal-title":"J Pain"},{"key":"B78-20241015","first-page":"CD012182","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B79-20241015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/M17-0155","article-title":"The effects of cannabis among adults with chronic pain and an overview of general harms: A systematic review","volume":"167","author":"Nugent","year":"2017","journal-title":"Ann Intern Med"},{"key":"B80-20241015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/1389201020666191202111534","article-title":"The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities","volume":"21","author":"Xu","year":"2020","journal-title":"Curr Pharm Biotechnol"},{"key":"B81-20241015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jorc.12062","article-title":"Saliva composition and upper gastrointestinal symptoms in chronic kidney disease","volume":"40","author":"Manley","year":"2014","journal-title":"J Ren Care"},{"key":"B82-20241015","first-page":"302","article-title":"Dyspepsia and gastric emptying in chronic renal failure patients","volume":"56","author":"Van Vlem","year":"2001","journal-title":"Clin Nephrol"},{"key":"B83-20241015","first-page":"CD009464","article-title":"Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy","volume":"2015","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B84-20241015","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","article-title":"Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: A randomised, placebo-controlled, phase II crossover trial","volume":"31","author":"Grimison","year":"2020","journal-title":"Ann Oncol"},{"key":"B85-20241015","doi-asserted-by":"crossref","first-page":"G78","DOI":"10.1152\/ajpgi.90285.2008","article-title":"Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats","volume":"295","author":"Duncan","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B86-20241015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5770\/cgj.23.399","article-title":"Mental health and cognition in older cannabis users: A review","volume":"23","author":"Vacaflor","year":"2020","journal-title":"Can Geriatr J"},{"key":"B87-20241015","doi-asserted-by":"crossref","first-page":"e1003524","DOI":"10.1371\/journal.pmed.1003524","article-title":"Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis","volume":"18","author":"Velayudhan","year":"2021","journal-title":"PLoS Med"},{"key":"B88-20241015","doi-asserted-by":"crossref","first-page":"e2035913","DOI":"10.1001\/jamanetworkopen.2020.35913","article-title":"Evaluation of THC-related neuropsychiatric symptoms among adults aged 50 years and older: A systematic review and metaregression analysis","volume":"4","author":"Velayudhan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B89-20241015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/17425255.2020.1754793","article-title":"Serious adverse effects of cannabidiol (CBD): A review of randomized controlled trials","volume":"16","author":"Dos Santos","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B90-20241015","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","article-title":"Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B91-20241015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.seizure.2021.05.014","article-title":"Two-center experience of cannabidiol use in adults with Dravet syndrome","volume":"91","author":"Silvennoinen","year":"2021","journal-title":"Seizure"},{"key":"B92-20241015","doi-asserted-by":"crossref","first-page":"e2120603","DOI":"10.1001\/jamanetworkopen.2021.20603","article-title":"Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: A randomized clinical trial","volume":"4","author":"Crippa","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B93-20241015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/can.2018.0060","article-title":"Endocannabinoid system and the kidneys: From renal physiology to injury and disease","volume":"4","author":"Chua","year":"2019","journal-title":"Cannabis Cannabinoid Res"},{"key":"B94-20241015","first-page":"1133","article-title":"Expression of cannabinoid receptors in human kidney","volume":"25","author":"Larrinaga","year":"2010","journal-title":"Histol Histopathol"},{"key":"B95-20241015","doi-asserted-by":"crossref","first-page":"7279","DOI":"10.1111\/jcmm.14570","article-title":"The cannabinoid receptor 1 is involved in renal fibrosis during chronic allograft dysfunction: Proof of concept","volume":"23","author":"Dao","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B96-20241015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ki.2015.63","article-title":"Cannabinoid receptor 1 is a major mediator of renal fibrosis","volume":"88","author":"Lecru","year":"2015","journal-title":"Kidney Int"},{"key":"B97-20241015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bph.14849","article-title":"Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease","volume":"177","author":"Udi","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B98-20241015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/bph.13338","article-title":"The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity","volume":"173","author":"Mukhopadhyay","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B99-20241015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.117.245522","article-title":"Selective cannabinoid 2 receptor stimulation reduces tubular epithelial cell damage after renal ischemia-reperfusion injury","volume":"364","author":"Pressly","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"B100-20241015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41419-018-0666-y","article-title":"Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression","volume":"9","author":"Tang","year":"2018","journal-title":"Cell Death Dis"},{"key":"B101-20241015","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1111\/bph.14495","article-title":"Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy","volume":"175","author":"Barutta","year":"2018","journal-title":"Br J Pharmacol"},{"key":"B102-20241015","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.2337\/db10-1809","article-title":"Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy","volume":"60","author":"Barutta","year":"2011","journal-title":"Diabetes"},{"key":"B103-20241015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.kint.2020.09.025","article-title":"Cannabinoid receptor type 2 promotes kidney fibrosis through orchestrating \u03b2-catenin signaling","volume":"99","author":"Zhou","year":"2021","journal-title":"Kidney Int"},{"key":"B104-20241015","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.kint.2018.05.023","article-title":"Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis","volume":"94","author":"Zhou","year":"2018","journal-title":"Kidney Int"},{"key":"B105-20241015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/ph14090863","article-title":"Detrimental effect of cannabidiol on the early onset of diabetic nephropathy in male mice","volume":"14","author":"Carmona-Hidalgo","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B106-20241015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/JCP.0000000000001089","article-title":"The potential for pharmacokinetic interactions between cannabis products and conventional medications","volume":"39","author":"Qian","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"B107-20241015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","article-title":"Current concepts in methadone metabolism and transport","volume":"6","author":"Kharasch","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B108-20241015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","article-title":"The effects of nabilone on sleep in fibromyalgia: Results of a randomized controlled trial","volume":"110","author":"Ware","year":"2010","journal-title":"Anesth Analg"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.11560821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:37Z","timestamp":1786369477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.11560821"}},"subtitle":["A Narrative Review"],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.11560821","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}